|
Name |
15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid
|
Molecular Formula | C20H32O3 | |
IUPAC Name* |
(5Z,8Z,11Z,13E)-15-hydroxyicosa-5,8,11,13-tetraenoic acid
|
|
SMILES |
CCCCCC(/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O)O
|
|
InChI |
InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14+
|
|
InChIKey |
JSFATNQSLKRBCI-USWFWKISSA-N
|
|
Synonyms |
15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid; 15-Hete; (5Z,8Z,11Z,13E)-15-hydroxyicosa-5,8,11,13-tetraenoic acid; ( inverted exclamation markA)15-HETE; 71030-36-9; (+/-)15-HETE; (5Z,8Z,11Z,13E)-15-HETE; 73836-87-0; 5,8,11,13-Eicosatetraenoicacid, 15-hydroxy-, (5Z,8Z,11Z,13E)-; (+/-)15-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid; SCHEMBL6382058; 15-HETE-[d8]; CHEBI:64017; LMFA03060087; HY-113336B; CS-0105808; 15-hydroxy-5Z,8Z,11Z,13E-icosatetraenoic acid; SR-01000946928; SR-01000946928-1; Q27132968
|
|
CAS | 71030-36-9 | |
PubChem CID | 9966861 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 320.5 | ALogp: | 5.1 |
HBD: | 2 | HBA: | 3 |
Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 57.5 | Aromatic Rings: | 0 |
Heavy Atoms: | 23 | QED Weighted: | 0.253 |
Caco-2 Permeability: | -5.223 | MDCK Permeability: | 0.00009400 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.093 | 20% Bioavailability (F20%): | 1 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.003 | Plasma Protein Binding (PPB): | 97.39% |
Volume Distribution (VD): | 0.241 | Fu: | 1.22% |
CYP1A2-inhibitor: | 0.198 | CYP1A2-substrate: | 0.734 |
CYP2C19-inhibitor: | 0.067 | CYP2C19-substrate: | 0.593 |
CYP2C9-inhibitor: | 0.127 | CYP2C9-substrate: | 0.991 |
CYP2D6-inhibitor: | 0.087 | CYP2D6-substrate: | 0.89 |
CYP3A4-inhibitor: | 0.124 | CYP3A4-substrate: | 0.076 |
Clearance (CL): | 4.406 | Half-life (T1/2): | 0.914 |
hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.709 |
Drug-inuced Liver Injury (DILI): | 0.029 | AMES Toxicity: | 0.306 |
Rat Oral Acute Toxicity: | 0.02 | Maximum Recommended Daily Dose: | 0.815 |
Skin Sensitization: | 0.936 | Carcinogencity: | 0.695 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.144 |
Respiratory Toxicity: | 0.94 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001094 | 0.641 | D0UE9X | 0.627 | ||||
ENC001549 | 0.564 | D0O1TC | 0.580 | ||||
ENC001103 | 0.524 | D06FEA | 0.489 | ||||
ENC001857 | 0.523 | D0G2MW | 0.426 | ||||
ENC001584 | 0.506 | D0Q5XX | 0.426 | ||||
ENC001535 | 0.506 | D04RGA | 0.413 | ||||
ENC001661 | 0.506 | D0V0IX | 0.392 | ||||
ENC001613 | 0.476 | D0I4DQ | 0.381 | ||||
ENC001552 | 0.452 | D0O1PH | 0.351 | ||||
ENC001544 | 0.435 | D0OR6A | 0.339 |